Combined treatments with a TKT inhibitor and vitamin B1 may thus pave the way to an alternative therapeutic regime and recommendation for adverse pathological outcomes involving excessive NET formation such as in severe sepsis or auto-inflammatory diseases. The gene discussed is TKT; the disease is Sepsis.